Clearthesis
Ask AIBuy ListWatchlist
TSLA
TSLA
MSFT
MSFT
META
META
GOOGL
GOOGL
AAPL
AAPL
NVDA
NVDA
See all followed stocks
Create free account
Already have an account? Sign in
Clearthesis
Sign up

Sign up free to access investment thesis for 500+ leading US stocks

AppleAppleMicrosoftMicrosoftNvidiaNvidiaAmazonAmazonAlphabetAlphabetMetaMetaTeslaTeslaBroadcomBroadcomAMDAMDTSMCTSMCArmArmQualcommQualcommMicronMicronMarvellMarvellOracleOracleAdobeAdobeSalesforceSalesforceServiceNowServiceNowCrowdStrikeCrowdStrikePalo AltoPalo AltoSpotifySpotifyCloudflareCloudflareShopifyShopifyVisaVisaMastercardMastercardRobinhoodRobinhoodCoinbaseCoinbasePalantirPalantirBerkshireBerkshireCostcoCostcoWalmartWalmartNetflixNetflixJPMorganJPMorgan
View all covered stocks →
Clearthesis
PricingPrivacyTermsContact

© 2026 ClearThesis, Inc.

For informational purposes only. Not investment advice. Clearthesis is not a registered investment adviser.

Following CLPT. You will receive monthly updates on how the investment thesis is playing out.
CLPT

ClearPoint NeuroCLPT

$11.21+2.8%
Updated Oct 5, 2026
Quality Score
2.9
Follow
Check for latest updates, earnings, and analyst price targetsLatest updates

On this page

Moat
Narrow
Profitability
Poor
Management
Adequate
Revenue growth
Solid
Valuation
Attractive
Sentiment
Bullish

Our thesis

  • ClearPoint Neuro makes computer systems that help surgeons perform brain surgery with extreme precision, focusing on minimally invasive procedures guided by real-time MRI scans. It generated $40 million in revenue last year and is growing by 18% as it moves beyond navigation into the larger neurocritical care market.
  • The company is positioning itself as the mandatory toll booth for the next generation of brain therapies, because its specialized equipment is required to deliver cell and gene treatments directly into the brain. Its moat rests on being deeply embedded in over 60 drug trials, which makes it very difficult for surgeons to switch to a rival once a drug is approved.
  • The primary growth driver is a projected commercial inflection in 2027, when several partner pharmaceutical companies expect to receive FDA approval for their brain-targeting drugs. This would shift ClearPoint from a research-focused business into a high-volume commercial supplier of the disposable tools used for every injection.
  • The biggest risk is the timing of drug approvals relative to the company's high cash burn, because any delay in the 2027 commercial timeline could force a dilutive capital raise. We lean cautious and view this as a watch item for now, because the current stock price demands a level of certainty that the company's financial results do not yet support.

Metrics we are tracking

Metric
Expectations
Status
Active Biopharma Partners
Growing and maintaining over 60 active partnerships
60+ as of Q2 2026
Quarterly Cash Burn
Operational cash use staying below $8 million per quarter
$7.5M average in H1 2026
Neurosurgery Navigation Revenue
Sustaining growth above 30% annually
62% in Q2 2026
Partner Clinical Trials
Having 10-15 clinical trials enrolling patients concurrently
10-15 expected in next 18 months

Numbers at a glance

Scale

Stock Price

$11.21

Market Cap

$336M

Revenue (TTM)

$40M

Rev. 5-yr CAGR

22.7%

Performance

ROIC

-34.2%

Gross Margin

62.6%

Op. Margin

-65.4%

FCF Margin

-74.0%

Valuation

P/E

-9.5x

EV/EBITDA

-13.5x

Analyst Target

$24

Quality scorecard

ClearPoint is a technically advanced medtech firm that is pivoting to become a drug delivery partner for big pharma. The key constraint is its high cash burn, which could force dilution before its commercial payoff arrives.

2.9
Moat Strength2

High switching costs in surgery are offset by the company's small scale and current losses.

Capital Efficiency1

ROIC is -40.5% as the company burns cash to build its biopharma and neurocritical care platforms.

Revenue Growth4

Revenue grew 18% overall with a 62% surge in navigation, showing strong adoption of new products.

Growth Runway5

The $0.5 billion neurocritical care market and upcoming gene therapy approvals provide a massive target.

Management3

Joseph Michael Burnett has a clear vision but has missed earnings estimates for four straight quarters.

AI Resilience3

AI has limited impact on the physical navigation hardware but could eventually assist in surgical planning.

Risk Resilience2

High cash burn and rising debt show a business that is currently vulnerable to market downturns.

Explore other popular stocks

NVDA
Nvidia
NVDA
AAPL
Apple
AAPL
MSFT
Microsoft
MSFT
AMZN
Amazon
AMZN
GOOGL
Alphabet
GOOGL
CLPT

Where could ClearPoint Neuro go from here?

Sign up free to unlock current fair value, 5 year price projections, and our final verdict.

Price today
$11
Fair value
Est. 5y price
Estimated from projected 5-year earnings and the multiple investors may pay in each case
or
No credit card required. Unsubscribe anytime.

Business Overview

What does it do?

ClearPoint Neuro is a growth business that earns money by selling a combination of specialized surgical hardware, software, and the disposable kits used in brain surgery. The core mechanism involves a specialized frame that attaches to a patient's head, allowing a surgeon to steer tools precisely using live MRI images as a guide. Money flows into the company from hospitals that buy the navigation systems and from pharmaceutical companies that pay for preclinical services to test how their drugs are delivered. The company takes a cut from every procedure through the sale of one-time-use sterile kits, ensuring that revenue grows as more surgeons adopt the technique.

Where does revenue come from?

The majority of revenue comes from the Neurosurgery Navigation and Therapy segment, which grew 62% last quarter due to the integration of the IRRAS acquisition. This segment provides the tools for intracranial bleeding and navigation, while the Biologics and Drug Delivery segment serves pharmaceutical partners. Capital equipment sales for hardware like the ClearPoint systems and laser units make up the remaining balance.

Revenue Breakdown

TOTAL$36M
Biologics and Drug Delivery Revenue+49.1%$14M37.3%
Functional Neurosurgery Navigation and Therapy-6.6%$9M23.4%
Functional Neurosurgery Navigation and Therapy - Disposable Products+0.0%$8M20.8%
Biologics and Drug Delivery - Disposable Products-41.6%$2M5.9%
Capital Equipment and Software Revenue-20.5%$2M5.0%
Capital Equipment and Software - Services+22.4%$973K2.7%
Other$2M4.9%

Who are its customers?

ClearPoint Neuro serves leading neurosurgery hospitals and over 60 active biopharma partners who use its technology for clinical trials. The company reported $10.9 million in total revenue for the second quarter of 2026, supported by clinical specialists who help surgeons during procedures. Its biopharma partners are particularly important because they represent the pipeline for future commercial sales. Management expects between 10 and 15 clinical trials to be actively enrolling patients using ClearPoint technology over the next 18 months.

What gives it staying power?

High switching costs provide staying power because surgeons who are trained on the ClearPoint system and software are unlikely to switch to a rival tool mid-career. Furthermore, once a drug is FDA-approved for delivery via ClearPoint, changing to another device would require new regulatory approvals for the drug maker.

Where is it headed?

The company is making a major strategic bet on its new robotic platform and Harmony software to automate neurosurgical workflows. This shift aims to make procedures more consistent and faster, which is necessary if biopharma partners are to scale their therapies to thousands of patients worldwide. Management is also expanding into focused ultrasound for non-invasive drug delivery to broaden their reach.

Financial Performance

Total revenue grew 18% to $10.9 million last quarter, but a 15% decline in the biopharma segment shows that growth is still lumpy and dependent on trial timing. This reflects a transition period as the company reorganizes its sales team to prepare for a much larger commercial rollout expected in 2027.

Revenue
↑ Growing
$0.0B · +18.9% CAGR · +33.3% YoY

Free cash flow is significantly negative, with the company using $15 million for operating activities in the first half of 2026. This gap between revenue and cash use reveals a heavy investment phase in new facilities like the ClearPoint Advanced Laboratories, which are not yet fully contributing to earnings.

Earnings (Net Income)
↓ Widening Loss
$0.0B net loss
Free Cash Flow
↓ Cash Burn
-$0.0B · -100.0% YoY

The balance sheet is under pressure, with long-term debt reaching $50.2 million against a cash balance that has fallen to $29.4 million. This level of leverage is high for a company that is still losing roughly $10 million a quarter, creating a clear need for revenue to accelerate soon.

ClearPoint Neuro is a business in a precarious transition that must reach profitability before its cash reserves run out. The single most important factor defining its financial character is the race between its 2027 commercial catalyst and its current cash burn rate.

Margins
↓ Compressing
Op. CF -64.7%
Op. Cash Flow
What's Working Well

The neurosurgery navigation segment is growing rapidly, with revenue up 62% last quarter as the new IRRAflow products gain traction. This success proves that the company can expand its product lineup and find a market for its new neurocritical care offerings beyond its traditional MRI business.

What to Watch

The cash burn rate is the primary risk, as the company used $16.7 million of its cash during the first half of the year. Management expects burn to decrease in the second half, but if they cannot slow the spending, they will be forced to raise capital on terms that could be painful for current owners.

Moat & Competition

Industry Stage
Growth Industry
EMERGINGGROWTHCONSOLIDATINGMATUREDECLINING

The neurosurgery navigation market is currently worth several billion dollars and is growing at roughly 15% annually as hospitals shift toward minimally invasive techniques. This is a high-margin industry where established players can hold their prices because the cost of the device is small compared to the risk of a surgical error. ClearPoint Neuro stands as a niche challenger that owns the MRI-guided segment, giving it a unique but narrow path to growth.

The Competition

The competitive dynamic is brutally difficult because ClearPoint must compete against massive companies like Medtronic and Stryker that already own the relationships with hospital purchasing departments. Barriers to entry are high due to the strict FDA regulations for brain surgery tools, but once a company is in, they must fight to keep their spot in the operating room. This environment makes long-term pricing power difficult to achieve without a unique technical advantage.

MDT
MedtronicMDT
SYK
StrykerSYK
RSW
RenishawRSW

Medtronic and Stryker are the primary threats, using their massive sales forces to bundle navigation tools with other hospital equipment. Brainlab and Renishaw attack from a technical angle, offering software and robotics that do not require an MRI, which is often more convenient for hospitals. Medtronic is the most dangerous threat because it can use its scale to undercut ClearPoint on price while offering a broader range of neurosurgery products.

ClearPoint Neuro is currently holding its ground in the niche MRI market, but it is under significant pressure to prove it can compete in the broader operating room.

The Moat
Moat Strength
Narrow Moat
Moat Trajectory
↗Widening
Moat Sources
NetworkEffectsSwitchingCostsCostAdvantageBrand& IPRegulatoryMoatEfficientScale
PresentPartialAbsent

The primary source of protection for ClearPoint is the intangible assets found in its proprietary software and its exclusive partnerships with biopharma companies. These partnerships create a technical lock-in where a drug is specifically tested and approved to be delivered only through a ClearPoint device. The most compelling proof is the list of 60 active biopharma partners who have built their clinical trials around ClearPoint technology.

Collective numbers show a business with high gross margins of 62.6% but deeply negative net margins, which suggests that the company has a product people want but lacks the scale to protect its profits. The current figures prove that ClearPoint is a good technical business, but it has not yet built a moat strong enough to withstand its own operating costs. ClearPoint lacks a strong moat because its specialized MRI focus is a small niche, and larger rivals can eventually replicate its drug delivery kits with enough research spending.

The moat is strengthening as the company accumulates more data and partner approvals. The move into neurocritical care via IRRAS and the new focused ultrasound partnership are signals that the company is building a more diverse platform that will be harder for a single rival to displace.

Management

Management Quality
Adequate
J
Joseph Michael Burnett
Chief Executive Officer
Execution
Mixed

Missed EPS estimates for four consecutive quarters despite steady revenue growth.

Capital Allocation
Adequate

Acquired IRRAS for $0.5B market entry but debt rose to $50M.

Alignment
Mixed

CEO holds approximately 1% of the company, which is modest for a small-cap.

Capital Allocation Track Record

Acquired IRRAS to diversify into the neurocritical care market and intracranial bleeding.
Invested $200M over 10 years to pivot the company toward biopharma drug delivery.
Entered a 10-year partnership for focused ultrasound to expand non-invasive offerings.

Joseph Michael Burnett has shown strong strategic vision by pivoting the company from a simple navigation tool into a biopharma partner, but his team has struggled with financial forecasting. While the strategic bets on drug delivery and neurocritical care look sound, the company has missed analyst earnings targets for the last four quarters, which suggests that management may be overly optimistic about how quickly these new markets will contribute to the bottom line. Trust in this team requires believing that their long-term vision for 2027 will eventually outweigh the current pattern of quarterly financial misses.

The company faces significant key-person risk with Joseph Burnett, who has been the architect of the biopharma pivot, and there is a high governance risk due to the rising debt levels. If Burnett were to leave, the company would lose its primary bridge to the pharmaceutical industry, and the board would face a difficult task in finding a leader with a similar dual background in medtech and drug development. Owners should watch the board's oversight of the cash burn closely, as the current strategy leaves very little room for error if the 2027 approvals are delayed.

Market view

NEUTRALBEARISHBULLISHBullish
Average target$23.50+110%vs $11.21 today
TodayAvg price
Low $22High $25
Strong Buy3 analysts
0Bearish
0Neutral
3Bullish
See analyst price targets

Outlook: Growth and risks

We expect revenue to grow from $0.0B in FY2026 to $0.2B in FY2031 (~31% CAGR), with EPS growing from $-1.30 to $0.17. Adoption of MRI-guided systems for drug delivery and neuro-navigation drives growth as hospitals upgrade surgical suites. Operating margins improve as sales and marketing costs are spread over a larger base of installed systems and recurring disposables. EPS grows faster than revenue because margins are expanding as the business reaches scale. Operating margin expected to reach ~5% by FY2031.

Projected revenue and EPS growth
FY2026
FY2027
FY2028
FY2029
FY2030
FY2031
Revenue
$0.1B
$0.1B
+20%
$0.1B
+17%
$0.1B
+86%
$0.2B
+23%
$0.2B
+19%
EPS (diluted)
$-1.30
$-1.20
$-0.98
$-0.94
$-0.46
$0.17
Growth Drivers

Commercial drug delivery inflection creates massive recurring revenue stream. If biopharma partners receive FDA approval in 2027, every procedure will require a ClearPoint kit, multiplying revenue without increasing sales costs.

IRRAS integration establishes a lead in neurocritical care. Successful adoption of IRRAflow for intracranial bleeding provides a second major growth engine that is not dependent on biopharma trials.

Robotic platform and Harmony software automate surgical workflow. Automation could lower the barrier to entry for hospitals, allowing the company to expand beyond high-end academic centers into community hospitals.

Risks

Partner clinical trials fail or FDA approvals are delayed. ClearPoint's entire growth story depends on drugs that it does not own, so a single partner's clinical failure can wipe out years of projected revenue.

Cash burn exhausts reserves before the 2027 commercial inflection. The company could run out of money and be forced to raise capital at a low stock price, diluting current owners to pay for survival.

Larger medical device rivals bundle competing navigation tools. If Medtronic or Stryker build a comparable drug delivery kit, they could use their massive sales force to push ClearPoint out of the operating room.

Metrics to Watch
  • •Active Biopharma PartnersGrowing and maintaining over 60 active partnerships
  • •Quarterly Cash BurnOperational cash use staying below $8 million per quarter
  • •Neurosurgery Navigation RevenueSustaining growth above 30% annually
  • •Partner Clinical TrialsHaving 10-15 clinical trials enrolling patients concurrently

Valuation

Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.

Our Stance
Medium confidence
Bullish

ClearPoint Neuro is worth $15 per share as it transitions from selling hardware to earning high-margin, recurring revenue from gene therapy partnerships that use its surgical disposable kits.

Fair Value
Current Price
$15
$11
$14$17
fair value range
Undervalued
Where could this stock be in 5 years?
Bull
$38
+239% vs today
Base
$18
+61% vs today
Bear
$5
-55% vs today
20272028202920302031
EPS$1.87$2.18$2.57$3.05$3.60
P/E8x7x6x6x5x
Price$15$15$15$18$18
How is the fair value calculated?

We value ClearPoint Neuro based on its projected sales for next year. Because the company is currently losing money to fund growth, its sales are the best indicator of its platform value. Next year's revenue of $56.6 million multiplied by an 8x multiple gives an enterprise value of $452 million, which works out to $15 per share after accounting for debt. We use a premium 8x multiple compared to mature peers like Integra LifeSciences (1x) or CONMED (1x) because ClearPoint is a high-growth "enabler" for the gene therapy market rather than just a tool maker. We used the FY2031 EPS of $0.17 from the projections to ensure long-term profitability is possible, but we believe the revenue-based approach better captures the value of the 50+ clinical partnerships active today.

Cross-check

A five-year cash flow analysis produces a fair value of $13, which is within 13% of our revenue-based answer. This math adds up the cash the company will generate as gene therapy approvals ramp up in 2028, then discounts those future dollars back at a 12% rate to account for the risk of clinical delays. The fact that both methods land near $13–$15 suggests the current stock price of $11.21 is undervaluing the long-term shift toward a recurring, high-margin business model.

What are the assumptions?
  • Revenue grows at a 25% yearly rate through 2029 as clinical trials move into commercial phases. This shift depends on the company moving from one-off equipment sales to selling disposable "kits" that are used in every procedure.
  • The company reaches a break-even point for cash flow by the end of 2027. We assume the high costs of expanding the sales and clinical teams are offset by the much higher profit margins on disposable products compared to hardware.
  • Total procedural volume across the installed base increases by 15% annually. This assumes neurosurgeons use the system for more than just niche cases as the Harmony software simplifies the workflow.
Show all assumptions ▾
  • Current price: $11.21 (company data, 2026-10-05)
  • β (5Y monthly): 1.29 (MarketBeat, 2026-10-05)
  • FY+1 Revenue Estimate: $56.55M (company data, 2026-10-05)
  • Diluted Shares: 30.3M (Calculated from Cap/Price)
  • Total Debt: $60M (company data, 2026-06-30)
  • Cash: $29.4M (company data, 2026-06-30)
What's the biggest risk?

The biggest risk is the persistent cash burn while waiting for biopharma partners to reach commercial approval. If partner trials are delayed, the company may exhaust its $29.4 million cash pile and be forced to issue more shares, which would knock roughly $4 off our per-share fair value. Watch the "cash used in operating activities" toward the end of 2026 to see if the burn rate is actually slowing as promised.

What could change the price?
↓

Bear case ($8): FY2026 revenue guidance is lowered again below $48 million due to slower adoption of the IRRAflow system; or Cash burn remains above $10 million per quarter, forcing a dilutive share sale before 2028.

↑

Bull case ($24): A major biopharma partner receives FDA approval for a brain-delivered gene therapy using ClearPoint’s navigation; or Quarterly product revenue growth accelerates above 40% as the IRRAS acquisition reaches full scale.

Final Verdict

Buy

Low convictionSituational

The business has a brilliant technical future but a difficult financial present, and the stock price is already paying for a victory that is years away. Until the company can prove it can slow its cash burn or secure a definitive commercial win in drug delivery, the risk of a dilutive capital raise remains too high. We would wait for a better entry price or a clear sign that the 2027 inflection is arriving on schedule. Worth owning if the price drops, because the long-term technical lead in drug delivery is real.

Should you own ClearPoint Neuro for the long term?

Sign up free to unlock following sections for CLPT

  • Valuation and fair value: Key assumptions, fair value math, plus bull and bear cases
  • Future outlook: Growth drivers, risks, and what to watch
  • 5-year projection: Revenue and EPS trajectory, and where the price could go
  • Final verdict: Buy, Watch, or Avoid with conviction and time horizon
or
No credit card required. Unsubscribe anytime.Already have an account? Sign in

Clearthesis wrote this report from 43 sources, including SEC filings, analyst estimates, industry research, and recent news.

Explore other popular stocks

NVDA
Nvidia
NVDA
AAPL
Apple
AAPL
MSFT
Microsoft
MSFT
AMZN
Amazon
AMZN
GOOGL
Alphabet
GOOGL

© 2026 Clearthesis.ai · Thesis written October 5, 2026

This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.

Latest updatesFollow CLPT
Sign up free for more access
  • Undervalued stock ideas every week
  • Track this thesis as it changes
  • Ask the AI analyst anything
Sign up free